Development and validation of an ultra‐fast and sensitive microflow liquid chromatography‐tandem mass spectrometry (MFLC‐MS/MS) method for quantification of LSD and its metabolites in plasma and application to a controlled LSD administration study in humans
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Lysergic acid diethylamide (LSD) is a semi‐synthetic hallucinogen that has gained popularity as a recreational drug and has been investigated as an adjunct to psychotherapy. Analysis of LSD represents a major challenge in forensic toxicology due to its instability, low drug concentrations, and short detection windows in biological samples. A new, fast, and sensitive microflow liquid chromatography (MFLC) tandem mass spectrometry method for the validated quantification of LSD, iso‐LSD, 2‐oxo 3‐hydroxy‐LSD (oxo‐HO‐LSD), and N‐desmethyl‐LSD (nor‐LSD) was developed in plasma and applied to a controlled pharmacokinetic (PK) study in humans to test whether LSD metabolites would offer for longer detection windows. Five hundred microlitres of plasma were extracted by solid phase extraction. Analysis was performed on a Sciex Eksigent MFLC system coupled to a Sciex 5500 QTrap. The method was validated according to (inter)‐national guidelines. MFLC allowed for separation of the mentioned analytes within 3 minutes and limits of quantification of 0.01 ng/mL. Validation criteria were fulfilled for all analytes. PK data could be calculated for LSD, iso‐LSD, and oxo‐HO‐LSD in all participants. Additionally, hydroxy‐LSD (HO‐LSD) and HO‐LSD glucuronide could be qualitatively detected and PK determined in 11 and 8 subjects, respectively. Nor‐LSD was only sporadically detected. Elimination half‐lives of iso‐LSD (median 12 h) and LSD metabolites (median 9, 7.4, 12, and 11 h for oxo‐HO‐LSD, HO‐LSD, HO‐LSD‐gluc, and nor‐LSD, respectively) exceeded those of LSD (median 4.2 h). However, screening for metabolites to increase detection windows in plasma seems not to be constructive due to their very low concentrations. Copyright © 2016 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
The paradoxical psychological effects of lysergic acid diethylamide LSD
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M., Williams, T. M., Williams, L. T., Underwood, R., Feilding, A., & Nutt, D. J. (2016) · Psychological Medicine · doi:10.1017/s0033291715002901 · Cited by 293
Over 30 million psychedelic users in the United States
Krebs, T. S., & Johansen, P.-Ø. (2013) · F1000Research · doi:10.12688/f1000research.2-98.v1 · Cited by 124
He, X., Kozak, M., & Nimkar, S. (2012) · Analytical Chemistry · doi:10.1021/ac3019476 · Cited by 36
Cited by
Modern clinical research on LSD
Liechti, M. E. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.86 · Cited by 236
“2-Oxo-3-hydroxy-LSD (Oxo-HOLSD) is the major metabolite of LSD and is detectable in urine for a longer time than LSD (Dolder et al, 2015a, b; Steuer et al, 2016).”
BackgroundInfluentialAlterations of consciousness and mystical-type experiences after acute LSD in humans
Liechti, M. E., Dolder, P. C., & Schmid, Y. (2017) · Psychopharmacology · doi:10.1007/s00213-016-4453-0 · Cited by 198
Self-citationPharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects
Dolder, P. C., Schmid, Y., Steuer, A. E., Kraemer, T., Rentsch, K. M., Hammann, F., & Liechti, M. E. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0513-9 · Cited by 133
“Samples were thawed for the first time for both analyses, this was also the case for study 2 (200 lg) because separate sets of samples were stored and used for the present [28] and previous [29] analyses.”
MethodSelf-citationMetabolism of lysergic acid diethylamide (LSD): an update
Libânio Osório Marta, R. F. (2019) · Drug Metabolism Reviews · doi:10.1080/03602532.2019.1638931 · Cited by 54
Metadata
- Authors
- Steuer, A. E., Poetzsch, M., Stock, L., Eisenbeiss, L., Schmid, Y., Liechti, M. E., & Kraemer, T.
- Venue
- Drug Testing and Analysis
- Publisher
- Wiley
- Published
- 2016-08-10
- Volume
- 9
- Issue
- 5
- Pages
- 788-797
- ISSN
- 1942-7603 (ISSN-L)
- 1942-7611
- OpenAlex
- W2517871020
- Cited by
- 41
- References
- 4
- FWCI
- 7.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development and validation of an ultra‐fast and sensitive microflow liquid chromatography‐tandem mass spectrometry (MFLC‐MS/MS) method for quantification of LSD and its metabolites in plasma and application to a controlled LSD administration study in humans. https://app.cochat.ai/papers/10.1002/dta.2042
- The paper
- Steuer, A. E., Poetzsch, M., Stock, L., Eisenbeiss, L., Schmid, Y., Liechti, M. E., & Kraemer, T. (2017). Development and validation of an ultra‐fast and sensitive microflow liquid chromatography‐tandem mass spectrometry (MFLC‐MS/MS) method for quantification of LSD and its metabolites in plasma and application to a controlled LSD administration study in humans. Drug Testing and Analysis. https://doi.org/10.1002/dta.2042
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.